Journal of Clinical Oncology
Articles in this Issue
Animated patient’s guide to melanoma: Assessing patient understanding, shared decision-making, and health outcomes.
9581 Background: Patients with melanoma who participate in informed, personalized-care discussions with their healthcare providers are better prepared to...
Deciphering colorectal cancer progression through integrative epigenomic analysis for precision therapeutics.
e15561 Background: Colorectal cancer (CRC), the third most prevalent cancer globally, remains a major cause of cancer-related mortality. Genomic and epige...
The prognostic role of TP53 mutations in MUTYH-associated colorectal cancers (MUTYH-CRCs).
e15724 Background: MUTYH-associated polyposis (MAP) is a hereditary Colorectal Cancer (CRC) syndrome caused by biallelic mutations in the MUTYH gene. The...
Temporal trends in non-Burkitt non-Hodgkin lymphoma–related mortality in the United States over the last three decades: An analysis of the Global Burden of Disease database.
e19076 Background: Non-Burkitt non-Hodgkin lymphoma (NHL) is a significant hematologic malignancy with considerable morbidity and mortality in the United...
Association of rapid progression on CDK4/6 inhibitor (CDKi) for metastatic HR+HER2- breast cancer (mHRBC) with genomic, proteomic, and immune microenvironment alterations.
e13102 Background: First-line CDKi and endocrine therapy has improved survival for many patients (pts) with mHRBC. Yet, some pts still experience rapid di...
Comparative analysis of demographics and outcomes in young versus average onset hospitalized gastrointestinal cancer patients in New York State.
1592 Background: Recent studies have shown an increasing incidence of gastrointestinal (GI) cancers among young patients. This study investigates clinical...
A phase 1 study of intracerebroventricular (ICV) delivery of bivalent chimeric antigen receptor (CAR) T-cells targeting EGFR and IL13Ra2 in patients with recurrent glioblastoma (rGBM).
102 Background: Outcomes in patients with rGBM are poor, with historical median overall survival (OS) of 6-9 months. Here we report the results from the d...
Clinical outcomes for low-income patients with early-onset breast cancer: An analysis of the National Inpatient Sample.
11183 Background: Despite recent global decreases in overall cancer incidence, the incidence of early-onset breast cancer (EOBC) is steadily increasing gl...
Feasibility of ChatGPT-4o in management of gynecologic oncologic patients in the emergency department.
5614 Background: Recent studies have highlighted the diagnostic and reasoning capabilities of ChatGPT in medicine. This study aims to evaluate the feasibi...
Identification of novel RNA biomarkers for the differential diagnosis of cutaneous melanoma and nevi.
9580 Background: The differential diagnosis of nevi and melanomas remains a significant clinical challenge, as misclassification can result in overtreatme...
Temporal trends in Hodgkin lymphoma-related mortality in the United States over the last three decades: Analysis of the Global Burden of Disease database.
e19040 Background: Hodgkin lymphoma, a subtype of lymphoma, exhibits a bimodal age distribution with peaks in the third decade and after age 50. Advanceme...
Envafolimab plus docetaxel in combination with or without trilaciclib versus docetaxel in pretreated advanced or metastatic non-small cell lung cancer (NSCLC): Preliminary analysis of an open-label, randomized, phase II trial.
e20562 Background: For patients with advanced NSCLC who fail first-line chemotherapy combined with immunotherapy, docetaxel as standard second line treatm...
Characteristics and outcome of breast cancers diagnosed in patients with germline ATM mutations.
10622 Background: The purpose of this study is to investigate clinicopathologic characteristics of invasive breast cancers diagnosed in individuals carryi...
The performance of MTAP homozygous deletion detection based on next-generation sequencing technology.
e14571 Background: Homozygous deletion of the MTAP occurs in 10-15% of all human cancers. MTAP catalyzes the conversion of MTA (S-adenosylmethionine) into...
Real-world outcomes and patterns of recurrence in a cohort treated with PACIFIC protocol: A single-center retrospective study.
e20089 Background: Lung cancer is the leading cause of cancer-related mortality. The PACIFIC trial established that one year of adjuvant durvalumab after...
Persistent racial disparities in AML survival in the FLT3 inhibitor era.
e18528 Background: FLT3 inhibitors for FLT3 mutated acute myelocytic leukemia (AML) were introduced in 2017 secondary to FDA approval. Historically, FLT3...
A phase 1, first-in-human study of IB-T101, an OUTLAST CAR-T product for the treatment of CD70-positive clear cell renal carcinoma.
TPS2676 Background: Relapsed or treatment-resistant clear cell renal cell carcinoma (ccRCC) poses a significant, unmet medical challenge, as patients cont...
A phase I dose-escalation study to assess the oncolytic virus VCN-01 safety and efficacy in refractory retinoblastoma patients.
10046 Background: Preclinical work demonstrated antitumor activity of VCN-01 (oncolytic adenovirus targeting the E2F pathway and expressing hyaluronidase)...
Unraveling relatlimab (RELA)-specific biology: Biomarker analyses in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with 1L nivolumab (NIVO) + RELA high-dose (HD) and platinum-doublet chemotherapy (PDCT).
8527 Background: The addition of RELA HD, a lymphocyte activation gene-3 (LAG-3) inhibitor, to NIVO + PDCT has improved clinical benefits vs NIVO + PDCT f...
PD-1 inhibitors versus PD-L1 inhibitors in PD-L1–negative advanced non-small cell lung cancer: A meta-analysis of survival outcomes.
e20585 Background: Immune checkpoint inhibitors (ICIs) which target programmed cell death protein 1 receptor (PD-1) or its ligand (PD-L1) are used extensi...
Comparative outcomes and sociodemographic disparities in moderate or excessive polypharmacy among older adults with solid tumors.
e13846 Background: Polypharmacy is pervasive among older adults with solid tumors, a high-risk population vulnerable to functional/cognitive decline and h...
AI-driven gamma-ray precision: Effect of convolutional neural networks on chemotherapy side effects.
e15000 Background: Chemotherapy remains a primary cancer treatment but causes significant systemic toxicity that impacts patient quality of life. Precisio...
Genomic testing in newly diagnosed patients with metastatic non small cell lung cancer (NSCLC): A report from a single centre within the Kaleido registry.
e13554 Background: The genomic testing rates in community oncology practices have been reported as low compared to academic centers, results mainly based...
Integrating gene signatures to guide HR+/HER2- MBC therapy in a diverse cohort (INSIGHT).
TPS1126 Background: Black women with breast cancer (BC) have a 40% higher mortality rate compared to Non-Hispanic White (NHW) women. Worse outcomes have b...
Envafolimab combined with albumin-bound paclitaxel and cisplatin in the neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, multicenter phase II study.
e16115 Background: Neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT) followed by esophagectomy has been taken as the currently the st...